Kyowa Hakko ( Kyowa Hakko )

Kyowa Hakko

Kyowa Hakko's picture

About Kyowa Hakko

Kyowa Hakko Kirin is a research-based life sciences company with special strengths in biotechnology. We are opening up the path toward the development of new biologics, and developing new medicines to meet medical needs that are currently not being satisfied by existing pharmaceuticals.

Kyowa Hakko press release, blog etc

09/21/2018 - 07:19 Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sezary Syndrome
09/21/2018 - 06:24 Kyowa Hakko Kirin Selected for Inclusion in Stock Indices GPIF Selected, FTSE4Good Index, and MSCI ESG Leaders Indexes
09/04/2018 - 23:21 Renaming of Kyowa Hakko Kirin (Singapore) Pte. Ltd.
08/21/2018 - 14:12 Kyowa Hakko Kirin Receives the Partial Change Approval of POTELIGEO in Japan
08/20/2018 - 12:13 Kyowa Hakko Kirin Announces Results of Early Phase 2 Trial of KW-6356 for Parkinson's Disease at IAPRD
08/08/2018 - 04:27 Kyowa Kirin Announces FDA Approval of Poteligeo (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sezary Syndrome
07/31/2018 - 02:53 Kyowa Hakko Kirin Submits Application for Additional Indication for Romiplostim (Recombinant) for Aplastic Anemia in Japan
06/04/2018 - 03:17 Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO
05/31/2018 - 02:52 Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl (RTA 402) for Diabetic Kidney Disease
05/30/2018 - 04:16 Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab
05/22/2018 - 13:31 Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
04/30/2018 - 13:36 Ultragenyx and Kyowa Kirin Announce Crysvita
04/17/2018 - 11:12 Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita (burosumab-twza) for the Treatment of Children and Adults with XLinked Hypophosphatemia (XLH)
04/17/2018 - 11:05 Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita
03/27/2018 - 21:05 Bardoxolone Methyl (RTA 402) Designated for the Treatment of Diabetic Kidney Disease under the Priority Review and Designation System by the Ministry of Health, Labour and Welfare
03/22/2018 - 19:41 Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
12/15/2017 - 00:27 Kyowa Kirin and Ultragenyx Announce Crysvita (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of XLinked Hypophosphatemia in Children
09/28/2016 - 01:05 Application seeking Approval for Additional formulation of ACOALAN in Japan